NCT02917577View on ClinicalTrials.gov

Hepatitis A Vaccine Dosing Regimens Among Pediatric Patients on Immunosuppressive Therapy

NACompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

November 22, 2016

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2023

Conditions
Autoimmune Rheumatologic Disease
Interventions
BIOLOGICAL

Avaxim Pediatric®

2 doses (0.5 mL each) 6 months apart of Avaxim Pediatric® vaccine.

BIOLOGICAL

Avaxim ® (adult)

2 doses (0.5 mL each) 6 months apart of Avaxim ® (adult) vaccine.

Trial Locations (1)

T3B6A8

Alberta Children's Hospital/University of Calgary, Calgary

All Listed Sponsors
lead

University of Calgary

OTHER

NCT02917577 - Hepatitis A Vaccine Dosing Regimens Among Pediatric Patients on Immunosuppressive Therapy | Biotech Hunter | Biotech Hunter